Jane Street Group LLC Sells 284,299 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Jane Street Group LLC cut its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 85.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 47,827 shares of the biotechnology company's stock after selling 284,299 shares during the quarter. Jane Street Group LLC's holdings in Heron Therapeutics were worth $73,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Quinn Opportunity Partners LLC purchased a new position in shares of Heron Therapeutics in the 4th quarter worth $581,000. JPMorgan Chase & Co. lifted its holdings in shares of Heron Therapeutics by 172.2% in the 4th quarter. JPMorgan Chase & Co. now owns 562,764 shares of the biotechnology company's stock valued at $861,000 after acquiring an additional 356,053 shares during the last quarter. CM Management LLC grew its position in Heron Therapeutics by 40.0% in the fourth quarter. CM Management LLC now owns 700,000 shares of the biotechnology company's stock worth $1,071,000 after acquiring an additional 200,000 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Heron Therapeutics in the fourth quarter worth about $208,000. Finally, Richmond Brothers Inc. increased its stake in Heron Therapeutics by 25.8% during the fourth quarter. Richmond Brothers Inc. now owns 642,339 shares of the biotechnology company's stock worth $983,000 after acquiring an additional 131,557 shares during the last quarter. Institutional investors own 80.01% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on HRTX. Wall Street Zen upgraded Heron Therapeutics from a "hold" rating to a "buy" rating in a report on Friday. Needham & Company LLC restated a "buy" rating and issued a $4.00 price target on shares of Heron Therapeutics in a research report on Friday, April 11th.

Heron Therapeutics Trading Up 5.0%

Shares of NASDAQ:HRTX opened at $2.10 on Monday. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The company has a market capitalization of $320.38 million, a price-to-earnings ratio of -11.67 and a beta of 1.15. The firm's 50-day moving average is $2.02 and its 200 day moving average is $1.87.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02. The business had revenue of $38.90 million for the quarter, compared to the consensus estimate of $37.08 million. As a group, equities analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.